WithdrawnPhase 2

Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation

Stopped: Resources not secured

United States0Started 2019-10

Plain-language summary

Stroke and abdominal aortic aneurysms (AAAs) are common and highly lethal vascular diseases. Angiogenesis and infiltration of inflammatory cells such as macrophages may cause stroke and AAAs. The purpose of this study is to test PET/CT and PET/MRI imaging to specifically detect those diseases using a new developed agent (18F-FPPRGD2) that can target angiogenesis and macrophages.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Greater than 18 year-old at the time of radiotracer administration * Provides written informed consent * Patients diagnosed with either carotid artery stenosis or abdominal aortic aneurysms (AAAs) as identified in Vascular Surgery, in whom a surgical procedure is scheduled * Able to remain still for duration of an imaging procedure (about one hour). Exclusion Criteria: * Less than 18 year-old at the time of radiotracer administration * Unable to provide written informed consent * Pregnant women * Prior carotid or abdominal surgery * History of radiation therapy to the neck and abdomen * MRI contraindications (including ferromagnetic objects or devices).

What they're measuring

SUVmax of 18F-FPPRGD2 uptake by lesions (carotid atherosclerotic plaque or AAA).

Timeframe: Up to 60 minutes post-injection (at time of scan)

Percent agreement of 18F-FPPRGD2 PET with pathology

Timeframe: Up to 60 minutes post-injection (at time of scan)

Trial details

NCT IDNCT02995642

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-09

View on ClinicalTrials.gov More Aortic Aneurysm, Abdominal trials